Article
Farnesyl Diphosphate Synthase Gene Associated with Loss of Bone Mass Density and Alendronate Treatment Failure in Patients with Primary Osteoporosis.
International journal of molecular sciences - 22 May 2024
Guaraná Werbson Lima, Lima Camilla Albertina Dantas, Barbosa Alexandre Domingues, Crovella Sergio, Sandrin-Garcia Paula
Abstract excerpt
Aminobisphosphonates (NBPs) are the first-choice medication for osteoporosis (OP); NBP treatment aims at increasing bone mineral density (BMD) by inhibiting the activity of farnesyl diphosphate synthase (FDPS) enzyme in osteoclasts. Despite its efficacy, inadequate response to the drug and side effects have been reported. The A allele of the rs2297480 (A > C) SNP, found in the regulatory region of the FDPS gene,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
